Biodefense Market - Overview and Outlook by Potential Growth By 2032

Biodefense Market Synopsis:

Biodefense Market Size Was Valued at USD 16.67 Billion in 2023, and is Projected to Reach USD 32.09 Billion by 2032, Growing at a CAGR of 7.6% From 2024-2032.

The biodefense market can be defined as the industry specialising in the generation of technologies, products and services that would help protect humanity against biological threats. Some of these threats may be natural epidemics, bioterrorism and biological warfare among people. The market comprises vaccines and diagnostics, therapeutics, and detection systems for use in the surveillance, prevention, and response to such threats. Biodefense strategies are implemented by government, international organizations and private entities in order to protect the population and states ‘security’.

The market that deals in biodefense products has been expanding steadily for the last decade as a result of the growing alarm about pandemics, bioterrorism and warfare. Governments and international organization are investing considerable dollars in upgrading biodefense systems. The rapid and accurate detection of COVID-19, coupled with developing global diagnostics and vaccine coverages, have become crucial market growth factors during the pandemic. Aside from cases of infectious disease epidemics, external conflicts have also increased alarms for terrorism so there was a systematic development towards biodefense.

Biodefense is a broad field of activity that covers a range of areas of activity: medical countermeasures such as vaccines, therapeutics, diagnostic equipment, and biologics, as well as surveillance and detection systems. Some of the leading market players working on new approaches are genomics, sequencing, biosensors, and AI-based surveillance platforms for a quicker and less harming biological threat. The market also enjoys supportive cross-over between PHAs, research institutions and the private sector that put in place strong, layered defence including

Biodefense Market Trend Analysis

Technological Advancements in Detection Systems

• The other major market driver in the biodefense market is the sustained growth in the innovative detection and surveillance systems. Owing to the increased threats of biological agents the need for quick identification of these agents has become important. Portable and digital biosensors, which are capable of detecting biological warfare agents with timers, are being used widely by military businesses. Many organisations are also employing AI and machine learning in identification of outbreaks and biohazards by and implementing them in surveillance systems. Other diagnostic tools are also advancing rapidly, particularly next generation genomic sequencing technologies which would allow researchers to map pathogens more effectively and rapidly thus contribute to prevention efforts.

Growing Government Funding and Public-Private Partnerships

• Several world governments are raising funding for biodefense as the idea of defending people against new biological dangers is becoming more imperative. With increasing focus on national security and health the market for biodefense related products has observerable potential for the companies involved. Public-Private partnerships are emerging more and more as government turn to private companies to produce vaccines, therapies, and high-tech diagnostics. This partnership enhances creativity and ensures the advancement of inventions that will create solutions in case of biological diseases and rogue attacks. Also, there is a trend for the companies to develop wider service range, where they can provide products and services to solve all the problems, starting from the prevention phase up to the response and restoration phase.

Biodefense Market Segment Analysis:

Biodefense Market is Segmented on the basis of Product Type, Application, End User, and Region

By Type, Vaccines segment is expected to dominate the market during the forecast period

• Based on type, the vaccines segment is expected to lead the biodefense market over the prediction period. This dominance stems from the fact that vaccines remain the ultimate weapon for countering the threat posed by biological pathogens regardless of their origin; natural or manmade. Among governments and health organizations, access to vaccines is considered as the leading defense against possible outbreaks with particular focus on prompt deployment of vaccines. The COVID-19 pandemic also underlined the need to develop new vaccines and increase investments in this segment in terms of velocity. Further improvements on the existing vaccine, particularly on improving the technology in the mRNA vaccines, are creating a great impact on the growth of the segment that is making it a strong factor in the biodefense system.

By Application, Military segment expected to held the largest share

• Based on the application, the military segment is expected to dominate the biodefence market throughout the forecast period. This is primarily because, modern/postmodern nations are given new reasons to enhance its biodefense strategic capability as part of their military capability amidst evidences of emerging biological threats to indigenous security of countries. The military spends a lot of money in sponsoring research and development and purchasing of biowarfare detection equipment and vaccines and other personnel protection mechanism. In addition, increased tensions between countries and the requirement to be prepared for hybrid warfare factors increasing this segment’s importance for defence budgets and strategies. In light of the mentioned trends of SYNO based military applications, tailoring efforts to fortify biodefense capabilities will generate consistent spending and improvement on the field.

Biodefense Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America is anticipated to drive the biodefense market in 2023:30; primarily owing to the U.S. forte in the biodefense industry. Biodefense in the United States is executed through various government machineries especially through the DoD, CDC and BARDA. In 2023, the North American region contributed to about 45% of the global biodefense market share due to the government emphasis on the probability of bioterrorism and amplified BIOWATCH spending after the COVID-19 pandemic stressed the significance of amplified spending in broader epidem, vaccine, diagnostic and surveillance advancements. Further, the current pharmaceutical and biotechnology industry support enhances this region’s hold on it.

Active Key Players in the Biodefense Market:

• Aeolus Pharmaceuticals (United States)
• Altimmune (United States)
• ANP Technologies (United States)
• Bavarian Nordic (Denmark)
• BBI Detection (United Kingdom)
• Cleveland BioLabs (United States)
• DynPort Vaccine Company (United States)
• Elusys Therapeutics (United States)
• Emergent BioSolutions (United States)
• Ichor Medical Systems (United States)
• Nanotherapeutics (United States)
• Ology Bioservices (United States)
• PharmAthene (United States)
• SIGA Technologies (United States)
• Soligenix (United States)
• Other Active Players

Key Industry Developments in the Biodefense Market:

• In February 2022, more than USD 10 million was revealed by Appili Therapeutics Inc. to develop ATI-1701, a biodefense vaccine candidate for the treatment of Francisella tularensis infection. The biodefense market is anticipated to grow and brand recognition will rise as a result.
• In August 2018, to expedite the development and production of a vaccine against the Lassa virus, CEPI (the Coalition for Epidemic Preparedness Innovations) established a new partnership with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. Collaboration aided businesses in expanding their product lines and boosting sales.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Biodefense Market by Product Type
 4.1 Biodefense Market Snapshot and Growth Engine
 4.2 Biodefense Market Overview
 4.3 Vaccines
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Vaccines: Geographic Segmentation Analysis
 4.4 Biothreat Detection Devices
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Biothreat Detection Devices: Geographic Segmentation Analysis

Chapter 5: Biodefense Market by Application
 5.1 Biodefense Market Snapshot and Growth Engine
 5.2 Biodefense Market Overview
 5.3 Military
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Military: Geographic Segmentation Analysis
 5.4 Civilian
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Civilian: Geographic Segmentation Analysis

Chapter 6: Biodefense Market by End-User
 6.1 Biodefense Market Snapshot and Growth Engine
 6.2 Biodefense Market Overview
 6.3 Hospitals & Clinics
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospitals & Clinics: Geographic Segmentation Analysis
 6.4 Ambulatory Care Centers
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Ambulatory Care Centers: Geographic Segmentation Analysis
 6.5 Others
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Others: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Biodefense Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions  
 7.2 AEOLUS PHARMACEUTICALS (UNITED STATES)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 ALTIMMUNE (UNITED STATES)
 7.4 ANP TECHNOLOGIES (UNITED STATES)
 7.5 BAVARIAN NORDIC (DENMARK)
 7.6 BBI DETECTION (UNITED KINGDOM)
 7.7 CLEVELAND BIOLABS (UNITED STATES)
 7.8 DYNPORT VACCINE COMPANY (UNITED STATES)
 7.9 ELUSYS THERAPEUTICS (UNITED STATES)
 7.10 EMERGENT BIOSOLUTIONS (UNITED STATES)
 7.11 ICHOR MEDICAL SYSTEMS (UNITED STATES)
 7.12 NANOTHERAPEUTICS (UNITED STATES)
 7.13 OLOGY BIOSERVICES (UNITED STATES)
 7.14 PHARMATHENE (UNITED STATES)
 7.15 SIGA TECHNOLOGIES (UNITED STATES)
 7.16 SOLIGENIX (UNITED STATES)
 7.17 OTHER ACTIVE PLAYERS

Chapter 8: Global Biodefense Market By Region
 8.1 Overview
 8.2. North America Biodefense Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Product Type
  8.2.4.1 Vaccines
  8.2.4.2 Biothreat Detection Devices
  8.2.5 Historic and Forecasted Market Size By Application
  8.2.5.1 Military
  8.2.5.2 Civilian
  8.2.6 Historic and Forecasted Market Size By End-User
  8.2.6.1 Hospitals & Clinics
  8.2.6.2 Ambulatory Care Centers
  8.2.6.3 Others
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Biodefense Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Product Type
  8.3.4.1 Vaccines
  8.3.4.2 Biothreat Detection Devices
  8.3.5 Historic and Forecasted Market Size By Application
  8.3.5.1 Military
  8.3.5.2 Civilian
  8.3.6 Historic and Forecasted Market Size By End-User
  8.3.6.1 Hospitals & Clinics
  8.3.6.2 Ambulatory Care Centers
  8.3.6.3 Others
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Russia
  8.3.7.2 Bulgaria
  8.3.7.3 The Czech Republic
  8.3.7.4 Hungary
  8.3.7.5 Poland
  8.3.7.6 Romania
  8.3.7.7 Rest of Eastern Europe
 8.4. Western Europe Biodefense Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Product Type
  8.4.4.1 Vaccines
  8.4.4.2 Biothreat Detection Devices
  8.4.5 Historic and Forecasted Market Size By Application
  8.4.5.1 Military
  8.4.5.2 Civilian
  8.4.6 Historic and Forecasted Market Size By End-User
  8.4.6.1 Hospitals & Clinics
  8.4.6.2 Ambulatory Care Centers
  8.4.6.3 Others
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 The Netherlands
  8.4.7.5 Italy
  8.4.7.6 Spain
  8.4.7.7 Rest of Western Europe
 8.5. Asia Pacific Biodefense Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Product Type
  8.5.4.1 Vaccines
  8.5.4.2 Biothreat Detection Devices
  8.5.5 Historic and Forecasted Market Size By Application
  8.5.5.1 Military
  8.5.5.2 Civilian
  8.5.6 Historic and Forecasted Market Size By End-User
  8.5.6.1 Hospitals & Clinics
  8.5.6.2 Ambulatory Care Centers
  8.5.6.3 Others
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Biodefense Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Product Type
  8.6.4.1 Vaccines
  8.6.4.2 Biothreat Detection Devices
  8.6.5 Historic and Forecasted Market Size By Application
  8.6.5.1 Military
  8.6.5.2 Civilian
  8.6.6 Historic and Forecasted Market Size By End-User
  8.6.6.1 Hospitals & Clinics
  8.6.6.2 Ambulatory Care Centers
  8.6.6.3 Others
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkiye
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Biodefense Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Product Type
  8.7.4.1 Vaccines
  8.7.4.2 Biothreat Detection Devices
  8.7.5 Historic and Forecasted Market Size By Application
  8.7.5.1 Military
  8.7.5.2 Civilian
  8.7.6 Historic and Forecasted Market Size By End-User
  8.7.6.1 Hospitals & Clinics
  8.7.6.2 Ambulatory Care Centers
  8.7.6.3 Others
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research